3T Biosciences

Executive Summary

3T Biosciences is a clinical-stage immunotherapy company pioneering next-generation T-cell receptor (TCR)-based therapeutics for solid tumors and immune-mediated diseases. The company's proprietary 3T-TRACE discovery platform enables systematic identification of novel tumor-specific targets and engineering of highly selective TCR-derived therapies, aiming to overcome key bottlenecks in targeted biotherapeutics and treat broad patient populations. Founded in 2015 and headquartered in South San Francisco, 3T Biosciences is positioned to address significant unmet needs in oncology and beyond. The company is advancing its pipeline of TCR-based candidates, with a focus on solid tumors where conventional therapies often fall short. Key upcoming catalysts include the initiation of first-in-human clinical trials, release of preclinical data for lead candidates, and potential partnership or collaboration announcements to expand its platform utility. As a private entity, 3T Biosciences relies on funding rounds and strategic alliances to fuel its development. The upcoming milestones will be critical to validating its platform and demonstrating clinical proof-of-concept, which could drive significant value inflection.

Upcoming Catalysts (preview)

• Q4 2026Initiation of first-in-human Phase 1/2 trial for lead TCR candidate70% success
• Q2 2026Presentation of preclinical data for novel tumor targets at major oncology conference80% success
• Q3 2026Announcement of strategic partnership or financing round60% success